Unicycive Therapeutics (NASDAQ:UNCY) Upgraded at Zacks Research

Unicycive Therapeutics (NASDAQ:UNCY) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on UNCY. Benchmark reissued a “speculative buy” rating and issued a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a research report on Thursday. B. Riley Financial reaffirmed a “buy” rating and set a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright cut their price objective on Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 13th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.75.

Unicycive Therapeutics Trading Down 2.3%

NASDAQ UNCY opened at $5.45 on Wednesday. The business’s 50-day moving average price is $5.80 and its 200 day moving average price is $6.61. Unicycive Therapeutics has a twelve month low of $3.71 and a twelve month high of $8.74. The company has a market capitalization of $151.78 million, a PE ratio of -3.11 and a beta of 1.79.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.41. Equities analysts predict that Unicycive Therapeutics will post -1.17 EPS for the current year.

Institutional Trading of Unicycive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new position in shares of Unicycive Therapeutics during the second quarter worth about $55,000. JPMorgan Chase & Co. grew its stake in shares of Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after buying an additional 21,525 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Unicycive Therapeutics during the 1st quarter valued at about $161,000. Citadel Advisors LLC acquired a new position in Unicycive Therapeutics during the 3rd quarter worth approximately $182,000. Finally, Bank of America Corp DE boosted its holdings in Unicycive Therapeutics by 19,327.6% in the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock worth $194,000 after acquiring an additional 29,378 shares during the period. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.